Patents by Inventor Noel Terrence Southall
Noel Terrence Southall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312511Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.Type: ApplicationFiled: February 17, 2023Publication date: October 5, 2023Inventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Patent number: 11634404Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.Type: GrantFiled: April 14, 2017Date of Patent: April 25, 2023Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSAS, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Publication number: 20230056497Abstract: Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables X, a, b, c, d, R1-4, R10-15 and R17-22 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving M2 phenotype of macrophages. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I and Formula II and Formula III are also disclosed.Type: ApplicationFiled: December 16, 2020Publication date: February 23, 2023Inventors: Raul Rolando Calvo, Bolormaa Baljinnyam, Andres Eduardo Dulcey, Udo Rudloff, Mark James Henderson, Juan Jose Marugan, Xin Hu, Noel Terrence Southall, Rushikesh Vilas Sable
-
Publication number: 20230000857Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.Type: ApplicationFiled: February 11, 2022Publication date: January 5, 2023Inventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
-
Publication number: 20220315548Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.Type: ApplicationFiled: August 28, 2020Publication date: October 6, 2022Inventors: Haoxing Xu, Lu Yu, Juan Jose Marugan, Raul Rolando Calvo, Natalia Julia Martinez, Noel Terrence Southall, Marc Ferrer, Xin Hu
-
Patent number: 11253511Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.Type: GrantFiled: January 4, 2017Date of Patent: February 22, 2022Assignees: The Johns Hopkins University, THE UNITED STATES OF AMERICA, as represented by thInventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
-
Publication number: 20210323941Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.Type: ApplicationFiled: April 14, 2017Publication date: October 21, 2021Inventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Patent number: 10301314Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: May 26, 2017Date of Patent: May 28, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng, Chen Wang
-
Patent number: 10202367Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: GrantFiled: June 12, 2015Date of Patent: February 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Publication number: 20190022083Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and CN compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.Type: ApplicationFiled: January 4, 2017Publication date: January 24, 2019Inventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
-
Patent number: 10039741Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of ? tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol in combination with cyclodextrin to a patient in need thereof.Type: GrantFiled: August 17, 2016Date of Patent: August 7, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Wei Zheng, Juan Jose Marugan, Ke Liu, Noel Terrence Southall, Christopher P. Austin
-
Publication number: 20170260192Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicants: The United States of America, as represented by the Secretary, Dept of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 9663521Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: December 17, 2012Date of Patent: May 30, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Publication number: 20170114053Abstract: Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.Type: ApplicationFiled: June 12, 2015Publication date: April 27, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of KansasInventors: Tsanyang Liang, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Shanshan He, Xin Hu, Jingbo Xiao, Marc Ferrer, Wei Zheng, Kevin J. Frankowski, Frank J. Schoenen, Kelin Li
-
Publication number: 20170027903Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of ? tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol in combination with cyclodextrin to a patient in need thereof.Type: ApplicationFiled: August 17, 2016Publication date: February 2, 2017Inventors: Wei Zheng, Juan Jose Marugan, Ke Liu, Noel Terrence Southall, Christopher P. Austin
-
Patent number: 9550742Abstract: The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.Type: GrantFiled: July 29, 2014Date of Patent: January 24, 2017Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer, Noel Terrence Southall, R. Benjamin Free, David Robert Sibley
-
Publication number: 20170001988Abstract: Disclosed are compounds of formula (I) (formula I), as antiviral agents, antineoplastic agents, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X and Y are independently CH or N, o is 0, 1 or 2, and E is absent or is (CR13R14)m, NH, or S, F is absent or is (CR15R16)n, C=O, or —SO2—, G is absent or is (CR17 CR18)r, H is absent or is C?O, or —SO2- and R1, Ar1, Ar2 are as defined in the specification. These compounds are antiviral agents and are contemplated in the treatment of viral infections, for example, hepatitis C, or are antineoplastic agents.Type: ApplicationFiled: November 20, 2014Publication date: January 5, 2017Inventors: Tsanyang Jake Liang, Marc Ferrer, Shanshan He, Xin Hu, Zongyi Hu, Juan Jose Marugan, Noel Terrence Southall, Jingbo Xiao, Wei Zheng
-
Publication number: 20160264570Abstract: The invention provides a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula I: wherein A, B, R1, R2, R10, and R11 are described herein, either alone or in combination with a second compound selected from elesclomol, NSC 174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1 152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: November 14, 2014Publication date: September 15, 2016Inventors: John C. McKew, Wei Zheng, Kim C. Williamson, Wenwei Huang, Wei Sun, Takeshi Tanaka, Seameen Jean Dehdashti, Noel Terrence Southall, Crystal Tobin Magle, Xiuli Huang, Paresma Rasiklal Patel, Myunghoon Kim
-
Publication number: 20160176831Abstract: The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.Type: ApplicationFiled: July 29, 2014Publication date: June 23, 2016Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer, Noel Terrence Southall, R. Benjamin Free, David Robert Sibley
-
Publication number: 20150265571Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of ? tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of ? tocopherol in combination with cyclodextrin to a patient in need thereof.Type: ApplicationFiled: May 13, 2015Publication date: September 24, 2015Inventors: Wei ZHENG, Juan Jose MARUGAN, Ke LIU, Noel Terrence SOUTHALL, Christopher P. AUSTIN